Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Biol Regul Homeost Agents ; 15(4): 351-8, 2001.
Article in English | MEDLINE | ID: mdl-11860223

ABSTRACT

As a natural consequence of the expression of the activated transforming rat Her-2/neu oncogene all mammary glands of female transgenic BALB/c (BALB-neuT) mice develop atypical epithelial hyperplasia which progresses to invasive carcinoma. A lobular carcinoma is palpable in all mammary glands of 33-week-old BALB-neuT mice. This progression is markedly delayed by systemic administration of IL-12. In a series of studies the best administration schedule, the lowest dose and the most effective administration time have been defined. The cellular and molecular mechanisms resulting in the delay of carcinogenesis have been established. By means of a series of downstream mediators IL-12 inhibits the angiogenic burst that goes along with the passage from preneoplastic to neoplastic and invasive lesions; it also recruits lymphoid cells in the mammary pad and activates their cytotoxicity towards neoplastic cells and newly formed vessels; and furthermore, it induces lymphoid cells to trigger antiangiogenic activities in neoplastic epithelial cells. Effective, low-dose and non-toxic IL-12 treatments may thus be envisaged as a possible option in the management of preneoplastic mammary lesions and in mammary cancer prevention.


Subject(s)
Interleukin-12/metabolism , Mammary Neoplasms, Animal/metabolism , Receptor, ErbB-2/metabolism , Animals , Cells, Cultured , Female , Humans , Interferon-gamma/metabolism , Mammary Neoplasms, Animal/prevention & control , Mice , Mice, Inbred BALB C , Models, Biological , Neovascularization, Pathologic
SELECTION OF CITATIONS
SEARCH DETAIL
...